WO2019121636A1

WO2019121636A1 - Composition comprising baicalin and an antioxidant compound

Info

Publication number: WO2019121636A1
Application number: PCT/EP2018/085424
Authority: WO
Inventors: Stéphane DOUEZAN; Maud WILLIEN
Original assignee: L'oreal
Priority date: 2017-12-19
Filing date: 2018-12-18
Publication date: 2019-06-27
Also published as: FR3075050B1; FR3075050A1

Abstract

The present invention relates to a composition, preferably a cosmetic composition, comprising at least one aqueous phase containing a compound chosen from baicalin and derivatives thereof, or a plant extract containing at least one of said compounds; and at least 0.2% by weight, relative to the total weight of the composition, of at least one antioxidant compound chosen from 4-hydroxybenzylidenemalonate derivatives, 4-hydroxycinnamate derivatives and 4-hydroxybenzyl malonate derivatives, and/or mixtures thereof. The invention also relates to a cosmetic process comprising at least one step which consists in applying such a composition to the skin, the lips and/or the hair.

Description

COMPOSITION COMPRISING BAICALIN AND AN ANTIOXIDANT

COMPOUND

The present application relates to a composition for topical application, comprising baicalin and/or a derivative thereof or an extract containing same, and to the use of said composition especially in the cosmetic field and in particular for caring for, for the hygiene of, for protecting and/or for making up keratin materials such as the skin, in particular bodily or facial skin, or the hair, preferably for caring for bodily or facial skin.

The present invention relates in particular to the field of cosmetic compositions for caring for keratin materials, and especially the skin.

Baicalin is a polyphenol which shows antioxidant activity. Its efficacy has especially been demonstrated in the fields of protecting the skin against solar radiation, premature aging of the skin and/or pollution.

There is thus a need to provide for consumers cosmetic compositions comprising baicalin, or an extract containing same, which have antioxidant efficacy, while at the same time having satisfactory cosmetic properties, in particular as regards the visual appearance of the product, and its sensory properties on application.

Many cosmetic compositions comprising baicalin as an antioxidant, or an extract containing same, are known in the prior art.

However, baicalin is very sparingly soluble in aqueous medium and in the usual cosmetic solvents, and recrystallization or degradation of the molecule may take place over time. Baicalin can thus destabilize the composition in which it is used.

Baicalin also causes yellowing of cosmetic compositions comprising it.

It is thus very difficult to incorporate into a composition, in particular into a cosmetic composition.

These phenomena are even more pronounced when the concentration of baicalin in the composition is high. Baicalin is thus generally included in the compositions described in the prior art in very small contents, thus limiting its effects.

It has been identified that the solubility of baicalin increases with the pH. However, at a pH above 6, baicalin is chemically unstable and degrades, thus bringing about its destruction.

Moreover, patent US 9 107 853 B2 relates to a chemical composition comprising baicalin in combination with a hydrotropic agent, such as nicotinamide. However, the presence of such a hydro tropic agent may be problematic with regard to the high content in which it is used, and to its intrinsic biological activity, which is not necessarily compatible with the products in which baicalin will be formulated.

The aim of the present invention is to solve the abovementioned technical problems.

In particular, a first object consists in obtaining a stable, preferably cosmetic, composition comprising baicalin, or an extract containing same.

Another object consists in providing a composition, preferably a cosmetic composition, comprising baicalin, or an extract containing same, the coloring of which is stable over time.

Furthermore, it would also be desirable to have available a composition, preferably a cosmetic composition, comprising baicalin, or an extract containing same, in which the baicalin is preserved from degradation or from recrystallization.

The aim of the present invention is to satisfy these needs.

Thus, a composition is described, preferably a cosmetic composition, comprising at least one aqueous phase containing:

- a compound chosen from baicalin and derivatives thereof, or a plant extract containing at least one of said compounds; and

- at least one antioxidant compound chosen from 4-hydroxybenzylidenemalonate derivatives, 4-hydroxycinnamate derivatives, 4-hydroxybenzyl malonate derivatives and/or mixtures thereof.

According to a first aspect, the present invention is directed toward a composition, preferably a cosmetic composition, comprising at least one aqueous phase containing:

- at least 0.2% by weight, relative to the total weight of the composition, of at least one antioxidant compound chosen from 4-hydroxybenzylidenemalonate derivatives, 4- hydroxycinnamate derivatives, 4-hydroxybenzyl malonate derivatives and/or mixtures thereof

According to a preferred embodiment, the antioxidant compound(s) are present in a content of between 0.2% and 10.0% by weight, better still in a content of between 0.3% and 5.0% by weight and better still in a content of between 0.5% and 3.0% by weight, relative to the total weight of the composition.

The inventors have discovered, surprisingly, that, in a composition according to the invention, baicalin undergoes little or no degradation and does not recrystallize despite its very low solubility.

The compositions according to the invention are advantageously stable and pleasant on application, even with high concentrations of baicalin, or of extracts containing same.

In particular, and as illustrated in the examples below, the compositions according to the invention remain stable, even after storage at temperatures above room temperature. Their coloring is stable over time. In particular, the compositions do not undergo yellowing and/or browning.

According to another of its aspects, another subject of the invention is a cosmetic process comprising at least one step which consists in applying a composition according to the invention to the skin, the lips and/or the hair.

For the purposes of the present invention, the term“keratin material” is intended to cover the skin, mucous membranes such as the lips, the nails and keratin fibers, such as the eyelashes and the hair. The skin, the lips and the hair are most particularly considered according to the invention

The term "skin" means all of the skin of the body, including the scalp, the mucous membranes, the semimucous membranes, and the skin integuments. The term "skin appendages" means the bodily hair, the eyelashes, the hair and the nails. More particularly, in the present invention, the skin of the neckline, of the neck and of the face, and especially the skin of the face, are considered.

Other characteristics, aspects and advantages of the invention will become apparent on reading the detailed description which follows.

BAICALIN AND DERIVATIVES OR EXTRACTS CONTAINING SAME

The compositions according to the invention comprise at least one compound chosen from baicalin and derivatives thereof, or a plant extract containing at least one of said compounds.

Baicalin and derivatives thereof have been described, as have the processes for the preparation thereof, in particular in application WO 2005/044281. They correspond to the general formula (I) below:

in which:

- each Xi, X₂, X₃, X₄, X₅, X_a, X_b, X_c, X_d, X_e and X_f independently denotes O or S;

- each Yi, Y₂, Y₃, Y₄, Y₅ and Y₆ independently denotes H or a (Ci-Cio)alkyl radical, in particular methyl;

- each R4, R₅, R_a, R_b and R_c independently denotes H, a (Ci-Cio)alkyl radical optionally substituted with 1 to 5 groups R_y, or a (Ci-Cio)alkyl-0-(Ci-Cio)alkyl radical, each (Ci- Cio)alkyl radical possibly being substituted with 1 to 5 groups R_y;

- each R_y independently denotes R, or a -(C2-Cio)alkenyl, -(C2-Cio)alkynyl, -(C₃- Cio)cycloalkyl, -(C8-Ci₄)bicycloalkyl, -(C8-Ci₄)tricyeloalkyl, -(C5-Cio)cycloalkenyl, -(CV Ci₄)tricyeloalkenyl, phenyl, naphthyl or -(Ci₄)aryl radical, each possibly being substituted with one or more radicals R_z;

- each Ri, R₂ and R₃ independently denotes R_q or a -(C2-Cio)alkenyl, -(C2-Cio)alkynyl, - (C₃-C io)cycloalkyl, -(C8-Ci₄)bicyeloalkyl, -(C8-Ci₄)tricyeloalkyl, -(C5-Cio)cycloalkenyl, - (Cs-C i₄)tricycloalkenyl, phenyl, naphthyl or -(Ci₄)aryl radical, each possibly being substituted with one or more radicals R_z;

- R_f is H,(Ci-Ci₂)alkyl, optionally substituted with 1 to 5 R_y or (Ci-Ci₂)alkyl-0-(Ci- Ci₂)alkyl radicals, each (Ci-Ci₂)alkyl radical possibly being substituted with 1 to 5 groups

R_y;

- each R_q, independently, is CN, OH, halogen, N₃, N0₂, N(R_Z)₂, =NR_Z, CH=NR_Z, NR_zOH, OR_z, COR_z, C(0)R_z, 0(C0)0R_z, SR_Z, S(0)R_z or S(0)₂R_z;

- each R_z, independently, is -(Ci-C₆)alkyl, -(C₂-C₆)alkenyl, -(C3-C8)cycloalkyl, -(C₃- Cs ycloalkenyl, phenyl, a heterocycle having 3 to 5 branches, CH(halo)₂ or C(halo)₃; and

- n is 0, 1, 2, 3, 4 or 5;

and also the salts thereof, the optical isomers thereof and/or the diastereoisomers thereof

Some compounds of formula (I) may have asymmetric centers and exist in different enantiomeric and diastereoisomeric forms. A compound of formula (I) may be in the form of an optical isomer or a diastereoisomer. According to the invention, the compounds of formula (I) also comprise their optical isomeric or diastereoisomeric forms and mixtures thereof, including racemic mixtures.

The term "-(Ci-Cio)alkyl" means a saturated, linear or branched, non-cyclic hydrocarbon-based chain containing from 1 to 10 carbon atoms. As examples of saturated linear -(Ci-Cio)alkyl radicals, mention may be made of: methyl, ethyl, n-propyl, n-butyl, - n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl. As examples of saturated branched -(Ci-Cio)alkyl radicals, mention may be made of isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl,

2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4- methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylpentyl, 2,2- dimethylhexyl, 3,3-dimethylpentyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylpentyl,

3-ethylpentyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl- 3-ethylpentyl, 2-methyl-4-ethylpentyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2- methyl-4-ethylhexyl, 2,2-diethylpentyl, 3,3-diehylhexyl, 2,2-diethylhexyl, 3,3- diethylhexyl.

The term "-(C₂-Cio)alkenyl" means an unsaturated, linear or branched non- cyclic hydrocarbon-based chain containing from 2 to 10 carbon atoms and comprising at least one carbon-carbon double bond. As examples of -(Ci-Cio)alkenyl radicals, mention may be made of: 2-pentenyl, 3 -methyl- l-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2- butenyl, l-hexenyl, 2-hexenyl, 3-hexenyl, l-heptenyl, 2-heptenyl, 3-heptenyl, l-octenyl, 2- octenyl, 3-octenyl, l-nonenyl, 2-nonenyl, 3-nonenyl, l-decenyl, 2-decenyl, 3-decenyl.

The term”-(C2-Cio)alkynyl" means an unsaturated, linear or branched non- cyclic hydrocarbon-based chain containing from 2 to 10 carbon atoms and comprising at least one carbon-carbon triple bond. As examples of (Ci-Cio)alkynyl radicals, mention may be made of: acetylenyl, propynyl, l-butynyl, 2-butynyl, l-pentynyl, 2-pentynyl, 3-methyl- l-butynyl, 4-pentynyl, l-hexynyl, 2-hexynyl, 5-hexynyl, l-heptynyl, 2-heptynyl, 6- heptynyl, l-octynyl, 2-octynyl, 7-octynyl, l-nonynyl, 2-nonynyl, 8-nonynyl, l-decynyl, 2- decynyl, 9-decynyl.

The term "-(C3-Cio)cycloalkyl” means a saturated hydrocarbon-based ring containing from 3 to 10 carbon atoms. As examples of -(C3-Cio)cycloalkyl radicals, mention may be made of: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl.

The term "-(C₈-Ci₄)bicycloalkyl" means a hydrocarbon-based bicycle containing from 8 to 14 carbon atoms and at least one saturated cycloalkyl ring. As examples of -(C8-Ci4)bicycloalkyl radicals, mention may be made of: indanyl, 1, 2,3,4- tetrahydronaphthyl, 5,6,7,8-tetrahydronaphthyl and perhydronaphthyl.

The term "-(C8-Ci4)tricycloalkyl" means a hydrocarbon-based tricycle containing from 8 to 14 carbon atoms and at least one saturated cycloalkyl ring. As examples of -(C8-Ci4)tricyeloalkyl radicals, mention may be made of: pyrenyl, 1, 2,3,4- tetrahydroanthracenyl, perhydroanthracenyl, aceanthrenyl, l,2,3,4-tetrahydropenanthrenyl, 5 , 6 , 7 , 8 -t etr ahydrophenanthreny 1 , p erhy drophenanthreny 1.

The term“-(C5-Cio)cycloalkenyl” means a non-aromatic hydrocarbon-based cyclic radical bearing at least one carbon-carbon double bond in the ring system and from 5 to 10 carbon atoms. As examples of -(C5-Cio)cycloalkenyl radicals, mention may be made of: cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cycloheptatrienyl, cyclooctenyl, cyclooctadienyl, cyclooctatrienyl, cyclooctatetraenyl, cyclononenyl, cyclononadienyl, cyclodecenyl, cyclodecadienyl.

The term “-(C8-Ci4)bicyeloalkenyl” means a hydrocarbon-based bicycle bearing at least one carbon-carbon double bond in each ring and from 8 to 14 carbon atoms. As examples of -(C₈-Ci₄)bicycloalkenyl radicals, mention may be made of: indenyl, pentalenyl, naphthalenyl, azulenyl, heptalenyl, l,2,7,8-tetrahydronaphthalenyl.

The term “-(C8-Ci4)tricyeloalkenyl” means a hydrocarbon-based tricycle bearing at least one carbon-carbon double bond in each ring and from 8 to 14 carbon atoms. As examples of -(C8-Ci4)tricyeloalkenyl radicals, mention may be made of: anthracenyl, phenalenyl, acenaphthalenyl, as-indacenyl, s-indacenyl.

The term“-(Ci4)aryl” means an aromatic carbocycle having 14 branches, such as anthryl and phenanthryl.

The term“heterocycle bearing 3 to 5 branches” means a saturated, unsaturated, aromatic or non-aromatic heteromonocycle bearing 3 to 5 branches containing carbon atoms and heteroatoms. A heterocycle bearing 3 or 4 branches may include up to 3 heteroatoms and a heterocycle bearing 5 branches may include up to 4 heteroatoms. Each heteroatom is independently chosen from a nitrogen, possibly quatemized, oxygen, and sulfur, including sulfoxide and sulfone. The heterocycle may be attached via any heteroatom or carbon atom. As examples of heterocycles bearing 3-5 branches, mention may be made of: furyl, thiophenyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, triazinyl, pyrrolidinonyl, pyrrolidinyl, hydantoinyl, oxiranyl, oxetanyl, tetrahydrofuryl and tetrahydro thiophenyl.

The term“halo” means a halogen atom such as F (fluorine), Cl (chlorine), Br (bromine) and I (iodine).

The term“-CH(halo)₂” means a methyl group in which two of the hydrogens are replaced with a halogen atom. Mention may be made, for example, of: -CHF₂, -CHCl₂, -CHBr₂, -CHBrCl, -CHC1I and -CHI₂.

The term“-CH(halo)3” means a methyl group in which three of the hydrogens are replaced with a halogen atom. Examples that may be mentioned include: -CF₃, -CF₂Cl, -CCl₃, -CBr₃, -CFBr₂ and -CI₃.

The term“salts of the compounds of formula (I)” means a salt formed with an inorganic or organic acid or else an inorganic or organic base.

As examples of acid salts, mention may be made of the sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, isonicotinate, lactate, salicylate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1 , 1’-methylenebis(2-hydroxy-3-naphthoate)) salts.

As examples of base salts, mention may be made of hydroxides of alkali metals such as sodium, potassium and lithium; hydroxides of alkaline-earth metals such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia and organic amines such as unsubstituted or hydroxy-substituted mono-, di- or trialkylamines; dicyclohexylamines; tributylamines; pyridine; N-methyl-N-ethylamine; diethylamine; triethylamine; mono-, bis- or tris(2-hydroxyalkylamines) such as mono-, bis- or tris(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris- (hydroxymethyl)methylamine, N,N-dialkyl-N-(hydroxyalkyl)amines, such as N,N- dimethyl-N-(2-hydroxyethyl)amine or tris(2-hydroxyethyl)amine; N-methyl-D-glucamine; and amino acids such as arginine and lysine.

According to a preferred form of the invention, at least one of the radicals Xi, X₂, X₃, X4, X₅, Xa, Xb, Xc, Xd, Xe and X_f is O.

According to a preferred form of the invention, at least one of the radicals Yi, Y₂, Y₃, Y₄, Y₅, Y₆ independently denotes H.

According to a preferred form of the invention, at least one of the radicals Yi, Y₂, Y3, Y₄, Y₆ independently denotes CH₃.

According to a preferred form of the invention, Ri denotes H or CH₃.

According to a preferred form of the invention, n is equal to 5.

According to a particularly preferred form, the composition of the invention comprises the baicalin corresponding to the general formula (II) below:

or a plant extract containing same.

This compound is described especially in patent application WO 2008/140440, especially in the form of a solution. Baicalin may be used in the form of a solution comprising an alkyl glycol containing from 2 to 7 carbon atoms, a polyol ether, and at least one antioxidant. Such an organic compound may be obtained as described in EP 1 400 579 (US 2004/0067894) relating to the synthesis of tetrahydroxyflavones, the general formula of which comprises baicalin.

The baicalin may be used in the form of an extract of plant origin. Baicalin is a polyphenol (flavone) extracted especially from scullcap root, in particular of Scutellaria baicalensis, having the INCI name: Scutellaria baicalensis root extract. It originates in traditional Chinese medicine. The various methods for preparing the extracts are described in patent application WO 2005/044281.

Baicalin is especially available from MMP under the trade name Baicalin 95

MM^®.

Baicalin is in the form of a yellow-colored powder, with a purity optionally greater than 90% or 95%. The baicalin crystals may be in the form of needles. It has very low solubility, in particular in water at spontaneous pH.

Preferentially, baicalin is included in the cosmetic composition in the fully dissolved form. There are no remaining baicalin crystals visible to the naked eye, under a polarized light microscope or via any technique known to those skilled in the art.

According to one particular embodiment, the compound(s) chosen from baicalin and/or derivatives thereof of formula (I), and also the salts thereof, the optical isomers thereof and/or the diastereoisomers thereof, are present in the compositions according to the invention in active material concentrations ranging from 0.05% to 10% by weight, better still from 0.1% to 8% by weight, even more preferably from 0.2% to 5% by weight relative to the total weight of the composition.

Preferably, baicalin or a derivative thereof is present in a content of greater than or equal to 0.01% by weight of active material, preferably greater than or equal to 0.1% by weight, better still greater than or equal to 0.2% by weight, relative to the total weight of the composition, and preferably in a content of between 0.01% and 5% by weight of active material, preferably between 0.1% and 4% by weight, and more particularly between 0.2% and 3% by weight, relative to the total weight of the composition.

ANTIOXIDANT COMPOUND

A composition according to the invention comprises at least one antioxidant compound chosen from 4-hydroxybenzylidene malonate derivatives, 4-hydroxycinnamate derivatives, 4-hydroxybenzyl malonate derivatives and/or mixtures thereof.

The term "antioxidant" means a compound which has activity on reactive oxygen species (ROS), and in particular free radicals.

Among the 4-hydroxybenzylidene malonate derivatives or the 4- hydroxycinnamate derivatives that are suitable for use according to the invention, use will preferentially be made of those of formula (III) below, and also the tautomeric forms thereof, the optical isomers thereof, the geometric isomers thereof; and/or mixtures thereof:

in which:

- A is a chromophoric group which absorbs UV radiation, comprising two monovalent groups bearing a carbonyl function;

- R14 represents a hydrogen atom, a linear or branched Ci-C₈ alkyl radical, or a linear or branched Ci-C₈ alkoxy radical;

- R15 denotes a linear or branched Ci-C₈ alkyl radical.

Among these compounds, use will more preferentially be made of those of formula (Ilia) below, and also the tautomeric forms thereof, the optical isomers thereof, the geometric isomers thereof; and/or mixtures thereof:

in which:

- Ri5 represents a hydrogen atom or a linear or branched Ci-C₈ alkyl radical;

- Rie is chosen from -C(0)CH₃, -C0₂Ri₈, -C(0)NH₂ and -C(0)N(Ri₉)₂;

- X denotes O or NH;

- Rn represents a linear or branched C₁-C₃₀ alkyl radical;

- Ris represents a linear or branched Ci-C₂o alkyl radical;

- each R19 represents, independently of each other, a linear or branched Ci-C₈ alkyl radical.

Among these compounds, use will more preferentially be made of those of formula (Illb) or (IIIc) below, and also the tautomeric forms thereof, the optical isomers thereof, the geometric isomers thereof; and/or mixtures thereof:

in which:

- Ri₆ denotes -C0₂Ri8;

- Rn denotes a linear or branched Ci-C₈ alkyl;

- Ris denotes a linear or branched Ci-Cs alkyl;

- X denotes O.

Use will preferably be made of the compound diethylhexyl syringylidenemalonate (INCI name: diethylhexyl syringylidenemalonate) of formula (Hid) below, and also the tautomeric forms thereof, the optical isomers thereof, and/or mixtures thereof:

Such a compound is sold especially under the trade name Oxynex ST by the company Merck.

Among the 4-hydroxybenzyl malonate derivatives that are suitable for use according to the invention, use will preferentially be made of those of formula (IV) below, and also the tautomeric forms thereof, the optical isomers thereof, the geometric isomers thereof; and/or mixtures thereof:

in which:

- R₁₄ represents a hydrogen atom, a linear or branched Ci-C₈ alkyl radical, or a linear or branched Ci-C₈ alkoxy radical;

- R₁₅ denotes a linear or branched Ci-C₈ alkyl radical.

Among these compounds, use will more preferentially be made of those of formula (IVa) below, and also the tautomeric forms thereof, the optical isomers thereof, the geometric isomers thereof; and/or mixtures thereof:

in which:

- R₁₅ represents a hydrogen atom or a linear or branched Ci-C₈ alkyl radical;

- Rie is chosen from -C(0)CH₃, -C0₂Ri₈, -C(0)NH₂ and -C(0)N(Ri₉)₂;

- X denotes O or NH;

- Rn represents a linear or branched C₁-C₃₀ alkyl radical;

- Ris represents a linear or branched Ci-C₂o alkyl radical;

- each R₁₉ represents, independently of each other, a linear or branched Ci-C₈ alkyl radical.

Among these compounds, use will more preferentially be made of those of formula (IVb) or (IVc) below, and also the tautomeric forms thereof, the optical isomers thereof, the geometric isomers thereof; and/or mixtures thereof:

in which:

- Ri₆ denotes -C0₂Ri₈; - Rn denotes a linear or branched Ci-C₈ alkyl;

- Ris denotes a linear or branched Ci-C₈ alkyl;

- X denotes O.

Use will in particular be made of the compound bis(2-ethylhexyl) 2-[(4- hydroxy-3,5-dimethoxyphenyl)methyl]propanedioate (INCI name: Bis-ethylhexyl hydroxy dimethoxy benzylmalonate) of formula (IVd) below, and also the tautomeric forms thereof, the optical isomers thereof, and/or mixtures thereof:

Such a compound is sold especially under the trade name Ronacare AP by the company Merck.

According to a particularly preferred embodiment of the invention, the antioxidant compound is diethylhexyl syringylidenemalonate (INCI name: diethylhexyl syringylidenemalonate) . Said at least one antioxidant compound may be present in a content ranging from 0.01% to 10% by weight, preferably ranging from 0.02% to 5% by weight and better still ranging from 0.05% to 3% by weight, relative to the total weight of the composition.

According to the invention, a composition comprises at least 0.2% by weight, relative to the total weight of the composition, of at least one antioxidant compound chosen from 4-hydroxybenzylidenemalonate derivatives, 4-hydroxycinnamate derivatives, 4- hydroxybenzyl malonate derivatives and/or mixtures thereof.

According to a preferred embodiment, the antioxidant compound(s) are present in a content of between 0.2% and 10.0% by weight, better still in a content of between 0.3% and 5.0% by weight, better still in a content of between 0.5% and 3.0% by weight, relative to the total weight of the composition. In particular, the mass ratio of baicalin or derivative(s)/antioxidant compound of a composition according to the invention is between 1 :50 and 30:1, preferably between 1 :20 and 20:1, in particular between 1 :10 and 15:1 and more preferentially between 3:10 and 10:1. COMPOSITION ACCORDING TO THF INVENTION

A composition according to the invention comprises an aqueous phase and optionally an oily phase.

According to a preferred embodiment, the composition according to the present invention has a water content of between 20% and 95% by weight and preferably between 30% and 85% by weight relative to the total weight of the composition.

The composition according to the invention preferably comprises an aqueous phase comprising water and a water-soluble organic solvent chosen, for example, from linear or branched C₂-C₄ alkanols, such as ethanol and isopropanol, propanol, butanol, polyols and polyol ethers, for instance 2-butoxyethanol, glycerol, diglycerol, propylene glycol, dipropylene glycol, butylene glycol, hexylene glycol, 1, 3-propanediol, pentylene glycol, polyethylene glycols, propylene glycol mono methyl ether, diethylene glycol mo no methyl ether and monoethyl ether, and also aromatic alcohols, for instance benzyl alcohol or phenoxy ethanol, and mixtures thereof.

The amount of organic solvent(s) may range, for example, from 0 to 30% by weight, preferably from 0.5% to 25% by weight, better still from 1% to 20% by weight and even better still from 2% to 15% by weight, relative to the total weight of the composition.

According to one embodiment, the composition according to the present invention is an emulsion.

According to one variant, the composition according to the invention is a simple emulsion.

According to one variant, the composition according to the invention is a multiple emulsion. It may be a triple emulsion.

According to one variant, the composition according to the invention is a direct simple emulsion. Thus, according to one embodiment, the composition according to the present invention is an oil-in-water (O/W) emulsion.

According to one variant, the composition according to the invention is an inverse simple emulsion. Thus, according to one embodiment, the composition according to the present invention is a water-in-oil (W/O) emulsion.

According to one variant, the composition according to the invention is an aqueous solution. Preferably, the composition is an emulsion, especially a water-in-oil or oil-in water emulsion, and preferably an oil-in-water emulsion.

Advantageously, the pH of the composition is between 5.0 and 6.0, especially between 5.1 and 5.9 and preferably between 5.2 and 5.8.

According to one embodiment, the composition, preferably a cosmetic composition, according to the invention comprises an acid and a base.

Base

According to one variant, the composition according to the invention comprises at least one base. The base is especially used to increase the pH of the initial aqueous solution comprising baicalin and consequently to dissolve it. It may also be used to adjust the final pH of the composition to between 5 and 6, especially between 5.1 and 5.9 and preferably between 5.2 and 5.8. The amount of base is thus the amount that is sufficient to fully dissolve the baicalin.

The base may be chosen from mineral bases, for instance alkali metal hydroxides, sodium hydroxide, potassium hydroxide, ammonium hydroxides, ammonia, organic bases, for instance monoethanolamine, diethanolamine, triethanolamine, triisopropylamine, tris [(2-hydroxy)- 1 -propyl)] amine, N,N-dimethylethanolamine, 2-amino- 2-methyl- 1 -propanol, 2-amino-2-methyl- 1 ,3-propanediol, triethylamine, dimethylaminopropylamine and amphoteric bases (i.e. bases containing both anionic and cationic functional groups) such as primary, secondary, tertiary or cyclic organic amines, and amino acids. Examples of amphoteric bases that may be mentioned include glycine, lysine, arginine, taurine, histidine, alanine, valine, cysteine, trihydroxymethylaminomethane (TRISTA), triethanolamine, and any mixture thereof.

According to a particular embodiment, the base of the composition is chosen from sodium hydroxide, potassium hydroxide, ammonium hydroxides, ammonia, monoethanolamine, diethanolamine, triethanolamine, tromethamine, and any mixture thereof.

According to a particular embodiment, the base of the composition is sodium hydroxide.

According to a particular embodiment, the base of the composition according to the invention is present at a mass concentration of less than 0.5%, or even less than 0.25% by mass, relative to the total mass of the composition.

Acid

According to one variant, the composition according to the invention comprises at least one acid. It may be used to adjust the final pH of the composition to between 5 and 6, especially between 5.1 and 5.9 and preferably between 5.2 and 5.8.

The acid may be chosen from mineral acids such as hydrochloric acid, sulfuric acid or nitric acid, organic acids such as acetic acid, lactic acid, glycolic acid, mandelic acid, citric acid or ascorbic acid, and any mixture thereof.

The acid may be chosen from organic acids, such as stearic acid, palmitic acid or myristic acid, hydrophobic-chain acrylate polymers, for instance Pemulen TR2, anionic aqueous-phase gelling agents, for instance acrylamidopropanesulfonic acid homopolymers, and any mixture thereof.

Advantageously, the acid may be chosen from carboxylic or sulfonic acid polymers and any mixture thereof.

Examples of acidic polymers that may be mentioned include modified or unmodified carboxyvinyl polymers, such as the products sold under the names Carbopol (CTFA name: carbomer) and Pemulen (CTFA name: Acrylates/C 10-30 alkyl acrylate crosspolymer) by the company Goodrich; optionally crosslinked and/or neutralized 2- acrylamido-2-methylpropane sulfonic acid polymers and copolymers, for instance the poly(2-acrylamido-2-methylpropanesulfonic acid) sold by the company Hoechst under the name “Hostacerin AMPS” (CTFA name: Ammonium polyacryldimethyltauramide); polysaccharide biopolymers such as xanthan gum, alginates, modified celluloses bearing at least one COOH group, for instance carboxyalkylcelluloses; and mixtures thereof.

According to a particular embodiment, the acid of the composition according to the invention is chosen from hydrochloric acid, acetic acid and citric acid, and any mixture thereof.

According to a particular embodiment, the acid of the composition according to the invention is citric acid.

According to a particular embodiment, the acid of the composition according to the invention is chosen from anionic aqueous-phase gelling agents, for instance acrylamidopropanesulfonic acid homopolymers (especially Hostacerin AMPS of INCI name: Ammonium polyacryloyldimethyltaurate).

According to a particular embodiment, the acid of the composition according to the invention is present at a mass concentration of less than 0.5%, or even less than 0.25% by mass, relative to the total mass of the composition.

Cosmetically acceptable active agents and/or excipients

According to a particular embodiment, the composition according to the invention also comprises cosmetically acceptable active agents and/or excipients other than the antioxidants used in a composition according to the invention.

The term“cosmetically acceptable” means compatible with keratin materials, having a pleasant color, odor and feel and not causing any unacceptable discomfort (stinging, tautness or redness) liable to discourage the consumer from using this composition.

According to one embodiment, the composition according to the invention also comprises at least one vitamin chosen from vitamin A (retinol), vitamin E (tocopherol), vitamins C (ascorbic acid), vitamin CG (ascorbyl glucoside), vitamin B5 (panthenol), derivatives of these vitamins (especially esters), and any mixture thereof.

According to a particular embodiment, the composition according to the invention also comprises vitamin E (tocopherol).

According to a particular embodiment, the composition according to the invention also comprises vitamin E (tocopherol) and/or vitamin CG (ascorbyl glucoside).

According to a particular embodiment, the composition according to the invention also comprises vitamin E (tocopherol) at a mass concentration of between 0.01% and 1.5%.

Preferably, the mass concentrations of vitamin range from 0.01% to 5%, and preferably from 0.1% to 2.5%, by mass relative to the total mass of said composition.

According to one embodiment, the composition according to the invention may also comprise at least one active principle (referred to as active agent) from a cosmetic viewpoint. The active agent may be chosen from enzymes; antioxidants other than the antioxidants used in a composition according to the invention; flavonoids; moisturizers; procyannidol oligomers; depigmenting agents; hydroxy acids; retinoids; melatonin; algal, fungal, plant, yeast or bacterial extracts; steroids; matt-effect agents; tensioning agents; ceramides; essential oils; and mixtures thereof; and any active agent that is suitable for the final purpose of the composition.

According to an advantageous embodiment, the composition, preferably a cosmetic composition, according to the invention may also comprise at least one active agent chosen from vitamin CG, vitamin E, ellagic acid, resveratrol, phenylethyl resorcinol, camosine, and any mixture thereof.

The active agent concentration in the composition of the invention may generally range from 0.0001% to 10% by mass.

According to one embodiment, the mass concentrations of active agents range from 0.01% to 5% and preferably from 0.1% to 3% by mass relative to the total mass of said composition.

Preferably, a composition according to the invention also comprises an antiaging active agent and/or an anti-UV active agent.

UV-SCREENING AGENTS

A composition according to the invention may also comprise at least one compound for screening out UVA and/or UVB.

Preferably, it may contain at least one UV-screening agent chosen from hydrophilic organic UV-screening agents, lipophilic organic UV-screening agents, insoluble organic UV-screening agents, mineral screening agents, and mixtures thereof.

According to an advantageous embodiment, the composition, preferably a cosmetic composition, according to the invention may also comprise at least one organic and/or mineral UV-screening agent (agent which screens out the UV radiation of sunlight).

The UV-screening agent is a UV-screening agent normally used in cosmetics. It may be chosen from the positive list contained in Annex VI of Regulation (EC) No 1223/2009, which specifies the list of UV-screening agents permitted in cosmetics.

The UV-screening agents of the composition according to the invention may be of various nature.

They may be lipophilic, hydrophilic or insoluble organic agents.

The term "lipophilic UV-screening agent" means any cosmetic or dermatological screening agent that can be fully dissolved in molecular form in a liquid fatty phase or that can be dissolved in colloidal form (for example in micellar form) in a liquid fatty phase.

The term "hydrophilic UV-screening agent" means any cosmetic or dermatological screening agent that can be fully dissolved in molecular form in a liquid aqueous phase or that can be dissolved in colloidal form (for example in micellar form) in a liquid aqueous phase.

The term "insoluble UV-screening agent" means any cosmetic or dermatological screening agent which is not defined either as a lipophilic UV-screening agent or as a hydrophilic UV-screening agent, and which is in the form of particles in aqueous phase or liquid fatty phase.

The UV-screening agents of the composition according to the invention may afford UVA and/or UVB photoprotection.

According to one embodiment, the composition also comprises at least one UV-screening agent chosen from hydrophilic organic UV-screening agents, lipophilic organic UV-screening agents, insoluble organic UV-screening agents, mineral screening agents, and any mixture thereof.

According to one embodiment, the composition may comprise one or more bis- resorcinyl triazine derivatives as described and prepared according to the syntheses indicated in patent application EP 0 775 698.

As examples of such compounds that may be used, mention may be made of:

- 2,4-bis { [4-(2-ethylhexyloxy)-2-hydroxy]phenyl} -6-(4-methoxyphenyl)- 1 ,3 ,5-triazine;

- 2,4-bis{[4-(3-(2-propyloxy)-2-hydroxypropyloxy)-2-hydroxy]phenyl}-6-(4- methoxyphenyl)- 1 ,3 ,5-triazine;

2,4-bis {[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-[4-(2-methoxyethylcarboxyl- phenylamino]- 1 ,3,5-triazine;

2,4-bis { [4-tris(trimethylsiloxysilylpropyloxy)-2-hydroxy]phenyl} -6-(4- methoxyphenyl)- 1 ,3 ,5-triazine;

2,4-bis { [4-(2"-methylpropenyloxy)-2-hydroxy]phenyl} -6-(4-methoxyphenyl)- 1,3,5- triazine;

2,4-bis{[4-(r,r,r,3',5',5',5'-heptamethyltrisiloxy-2"-methylpropyloxy)-2- hydroxy]phenyl}-6-(4-methoxyphenyl)-l,3,5-triazine;

2,4-bis{[4-(3-(2-propyloxy)-2-hydroxypropyloxy]-2-hydroxy]phenyl}-6-[(4- ethylcarboxyl)phenylamino]- 1 ,3 ,5-triazine;

2,4-bis { [4-(2-ethylhexyloxy)-2-hydroxy]phenyl} -6-( 1 -methylpyrrol-2-yl)- 1 ,3 ,5- triazine.

Use may be made more particularly of at least the compound 2,4-bis{[4-(2- ethyl-hexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-l,3,5-triazine or Bis- Ethylhexyloxyphenol Methoxyphenyl Triazine (INCI name) such as the product sold under the trade name Tinosorb S by Ciba-Geigy.

According to one embodiment, the composition may comprise one or more dibenzoylmethane derivatives. Mention may be made especially, in a nonlimiting manner, of:

- 2-methyldibenzoylmethane,

- 4-methyldibenzoylmethane,

- 4-isopropyldibenzoylmethane,

- 4-tert-butyldibenzoylmethane,

- 2,4-dimethyldibenzoylmethane,

- 2,5-dimethyldibenzoylmethane,

- 4,4’ -diisopropyldibenzoylmethane,

- 4,4’ -dimethoxydibenzoylmethane,

- 4-tert-butyl-4’-methoxydibenzoylmethane,

- 2 -methyl-5 -isopropyl-4’-methoxydibenzoylmethane,

- 2 -methyl-5 -tert-butyl-4’ -methoxydibenzoylmethane,

- 2,4-dimethyl-4’-methoxydibenzoylmethane,

- 2, 6-dimethyl-4-tert-butyl-4’-methoxydibenzoylmethane.

According to one embodiment, the composition may comprise one or more benzylidenecamphor derivatives. Mention may be made especially of:

- 3 -benzylidenecamphor, manufactured under the name Mexoryl SD by Chimex,

- 4-methylbenzylidenecamphor, sold under the name Eusolex 6300 by Merck,

- benzylidenecamphorsulfonic acid, manufactured under the name Mexoryl SL by Chimex,

- camphor benzalkonium methosulfate, manufactured under the name Mexoryl SO by Chimex,

- polyacrylamidomethylbenzylidenecamphor, manufactured under the name Mexoryl SW by Chimex,

- terephthalylidenedicamphorsulfonic acid, manufactured under the name Mexoryl SX by Chimex.

The organic UV-screening agents may also be chosen from anthranilic derivatives; cinnamic derivatives; salicylic derivatives; benzophenone derivatives; phenylbenzotriazole derivatives; benzalmalonate derivatives, especially those mentioned in patent US 5 624 663; phenylbenzimidazole derivatives; imidazolines; 4,4-diarylbutadienes; bis-benzazolyl derivatives, such as those described in patents EP 6 693 23 and US 2 463 264; p-aminobenzoic acid (PABA) derivatives; methylenebis(hydroxyphenolbenzotriazole) derivatives, such as those described in patent applications US 5 237 071, US 5 166 355, GB 2303549, DE 197 26 184 and EP 893 119; benzoxazole derivatives such as those described in patent applications EP 0 832 642, EP 1 027 883, EP 1 300 137 and DE 10162844; screening polymers and screening silicones such as those described especially in particular in patent application WO 93/04665; a-alkylstyrene derivatives such as those described in patent application DE 19855649; 4,4-diarylbutadienes as described in patent applications EP 0 967 200, DE 19746654, DE 19755649, EP 1 008 586, EP 1 133 980 and EP 133 981; other merocyanine derivatives such as those described in patent applications WO 04006878, WO 05058269 and WO 06032741, and mixtures thereof

As examples of organic UV-screening agents used in the composition according to the invention, mention may be made of those denoted below under their INCI name:

Lipophilic UV-A screening agents

Dibenzoylmethane derivatives:

Isopropyldibenzoylmethane;

Butylmethoxydibenzoylmethane. Aminobenzophenones :

n-Hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate sold especially under the trade name Uvinul A+ by BASF;

1 , l'-(l ,4-Piperazinediyl)bis[l-[2-[4-(diethylamino)-2- hydroxybenzoyl]phenyl]methanone (CAS 919803-06-8).

According to a preferred embodiment, the composition according to the invention comprises the UV-screening agent of INCI name diethylamino hydroxybenzoyl hexyl benzoate (sold, for example, under the trade name Uvinul A +).

Anthranilic derivatives:

Menthyl anthranilate sold in particular under the trade name Neo Heliopan MA by Symrise.

4,4-Diarylbutadiene derivatives:

1 , 1 -Dicarboxy-(2,2’-dimethylpropyl)-4,4-diphenylbutadiene.

Merocyanine derivatives:

Octyl 5-N,N-diethylamino-2-phenylsulfonyl-2,4-pentadienoate.

According to a particular embodiment, the composition according to the invention comprises butylmethoxydibenzoylmethane (also known under the name Avobenzone).

Hydrophilic UV-A screening agents:

The bis-benzazolyl derivatives as described in patents EP 669 323 and US 2 463 264 and more particularly the compound disodium phenyl dibenzimidazotetrasulfonate sold under the trade name Neo Heliopan AP by Symrise.

According to a particular embodiment, the composition according to the invention comprises terephthalylidenedicamphorsulfonic acid (sold for example under the name Mexoryl SX).

Lipophilic UV-B screening agents: para - Aminobenzoates : Ethyl PABA;

Ethyl dihydroxypropyl PABA;

Ethylhexyl dimethyl PABA (Escalol 507 from ISP).

Salicylic derivatives:

Homosalate sold in particular under the name Eusolex HMS by Rona/EM

Industries;

Ethylhexyl salicylate sold in particular under the name Neo Heliopan OS by

Symrise;

Dipropylene glycol salicylate sold in particular under the name Dipsal by

Scher;

TEA salicylate sold under the name Neo Heliopan TS by Symrise.

Cinnamates:

Ethylhexyl methoxycinnamate sold in particular under the trade name Parsol MCX by DSM Nutritional Products, Inc.;

Isopropyl methoxycinnamate;

Isoamyl methoxycinnamate sold in particular under the trade name Neo Heliopan E 1000 by Symrise;

Diisopropyl methylcinnamate;

Cinnoxate;

Glyceryl ethylhexanoate dimethoxycinnamate. b.b-Diphcnylacrylatc derivatives:

Etocrylene sold in particular under the trade name Uvinul N35 by BASF;

Octocrylene sold in particular under the trade name Uvinul N539 by BASF.

Benzylidenecamphor derivatives:

3-Benzylidenecamphor, manufactured under the name Mexoryl SD by

Chimex;

Methylbenzylidenecamphor, sold especially under the name Eusolex 6300 by

Merck;

Polyacrylamidomethylbenzylidenecamphor, manufactured under the name Mexoryl SW by Chimex. Triazine derivatives:

Ethylhexyl triazone sold especially under the trade name Uvinul T150 by

BASF;

Diethylhexylbutamidotriazone sold especially under the trade name Uvasorb HEB by Sigma 3 V;

2.4.6-Tris(dineopentyl 4’-aminobenzalmalonate)-s-triazine;

2.4.6-Tris(diisobutyl 4’-aminobenzalmalonate)-s-triazine;

2.4-Bis(dineopentyl 4’-aminobenzalmalonate)-6-(n-butyl 4’-aminobenzoate)-s- triazine;

2.4-Bis(n-butyl 4^,-aminobenzoate)-6-(aminopropyltrisiloxane)-s-triazine;

the symmetrical triazine screening agents described in patent US 6 225 467, patent application WO 2004/085 412 (see compounds 6 and 9) or the document Symmetrical Triazine Derivatives, IP.COM Journal, IP.COM Inc West Henrietta, NY, US (September 20, 2004), in particular 2,4,6-tris(biphenyl)-l,3,5-triazine (in particular 2,4,6- tris(biphenyl-4-yl-l,3,5-triazine) and 2,4,6-tris(terphenyl)-l,3,5-triazine, the latter two screening agents being described in the Beiersdorf patent applications WO 06/035000, WO 06/034982, WO 06/034991, WO 06/035007, WO 2006/034992 and WO 2006/034985).

Imidazoline derivatives:

Ethylhexyl dimethoxybenzylidene dioxoimidazoline propionate. Benzalmalonate derivatives:

Polyorganosiloxanes containing benzalmalonate functions, for instance Polysilicone-l5, sold in particular under the trade name Parsol SLX by DSM Nutritional Products, Inc.;

Dineopentyl 4’ -methoxybenzalmalonate.

According to a particular embodiment, the composition according to the invention comprises one or more UV-screening agents chosen from the following screening agents: Ethylhexyl salicylate (sold especially under the name Neo Heliopan OS by Symrise); Octocrylene (sold especially under the trade name Uvinul N539 by BASF); Ethylhexyl triazone (sold especially under the trade name Uvinul T150), and any mixture thereof. Hydrophilic UV-B screening agents:

The following / -aminobcnzoic acid (PABA) derivatives:

PABA;

Glyceryl PABA; and

PEG-25 PABA, sold especially under the trade name Uvinul P25 by BASF; Phenylbenzimidazolesulfonic acid, sold especially under the trade name Eusolex 232 by Merck;

ferulic acid;

salicylic acid;

DEA methoxycinnamate;

benzylidenecamphorsulfonic acid, manufactured under the name Mexoryl SL by Chimex;

camphor benzalkonium methosulfate, manufactured under the name Mexoryl SO by Chimex.

Mixed UVA and UVB lipophilic screening agents:

Benzophenone derivatives

Benzophenone-l, sold especially under the trade name Uvinul 400 by BASF; Benzophenone-2, sold especially under the trade name Uvinul D50 by BASF; Benzophenone-3 or Oxybenzone, sold especially under the trade name Uvinul M40 by BASF;

Benzophenone-6, sold especially under the trade name Helisorb 11 by

Norquay;

Benzophenone-8, sold especially under the trade name Spectra-Sorb UV-24 by American Cyanamid;

Benzophenone- 10 ;

Benzophenone- 11 ;

Benzophenone- 12.

Phenylbenzotriazole derivatives:

Drometrizole trisiloxane, sold especially under the name Silatrizole by Rhodia Chimie or manufactured under the name Meroxyl XL by the company Chimex;

Methylenebis(benzotriazolyl)tetramethylbutylphenol, sold in solid form in particular under the trade name Mixxim BB/100 by Fairmount Chemical, or in micronized form as an aqueous dispersion in particular under the trade name Tinosorb M by Ciba Specialty Chemicals.

According to a particular embodiment, the composition according to the invention comprises one or more UV-screening agents chosen from the following screening agents: Drometrizole trisiloxane (sold especially under the name Silatrizole by Rhodia Chimie or manufactured under the name Meroxyl XL by the company Chimex), Methylenebis(benzotriazolyl)tetramethylbutylphenol optionally in micronized form, and any mixture thereof.

Benzoxazole derivatives:

2,4-Bis[5-(l-dimethylpropyl)benzoxazol-2-yl-(4-phenyl)imino]-6-(2- ethylhexyl)imino-l,3,5-triazine sold especially under the name Uvasorb K2A by Sigma 3V.

Mixed UVA and UVB hydrophilic screening agents:

Benzophenone derivatives including at least one sulfonic radical, such as:

Benzophenone-4 sold especially under the trade name Uvinul MS 40 by BASF;

Benzophenone-5; and

Benzophenone-9.

UV-screening agents of the merocyanine family:

The composition, preferably a cosmetic composition, according to the invention may comprise one or more UV-screening agents of the merocyanine family. Mention may also be made of the merocyanine-type screening agents in particular prepared according to the protocols described in WO 2007/071582, in IP.com Journal (2009), 9(5A), 29-30 IPCOM000182396D under the title Process for producing 3-amino-2-cyclohexan-l- ylidene compounds and in US 4 749 643 (column 13, line 66 - column 14, line 57 and the references cited in this regard). According to one embodiment, the composition comprises one or more UV- screening agents chosen from terephthalylidenedicamphorsulfonic acid, butylmethoxydibenzoylmethane, drometrizole trisiloxane, octocrylene, ethylhexyl salicylate, methylenebis(benzotriazolyl)tetramethylbutylphenol, ethylhexyl triazone, bis(ethylhexyloxyphenyl)methoxyphenyltriazine, diethylaminohydroxybenzoylhexyl benzoate, and any mixture thereof.

According to one embodiment, the composition comprises at least one organic UV-screening agent chosen from the following: drometrizole trisiloxane, ethylhexyl triazone and diethylaminohydroxybenzoylhexyl benzoate, and any mixture thereof. It may also comprise one or more screening agents of non-organic, for example mineral, nature.

According to one embodiment, the composition comprises one or more lipophilic UV-screening agents.

According to one embodiment, the amount of the non-encapsulated organic UV-screening agent(s) present in the composition according to the invention may range from 0.5% to 50% by mass, relative to the total mass of the composition. It ranges, for example, from 5% to 50% by mass or, for example, from 10% to 40% by mass and even more, for example, ranges from 20% to 40% by mass, relative to the total mass of the composition.

According to a particular embodiment, the concentration of UV-screening agents in the composition according to the invention ranges from 1% to 50% and preferably from 1% to 40% by mass, relative to the total mass of the composition.

The composition of the invention may also comprise mineral UV-screening agents, which are generally pigments. The pigments may or may not be coated.

The coated pigments are pigments that have undergone one or more surface treatments of chemical, electronic, mechanochemical and/or mechanical nature with compounds as described, for example, in Cosmetics & Toiletries, February 1990, Vol. 105, pages 53-64, such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron or aluminum salts of fatty acids, metal alkoxides (of titanium or aluminum), polyethylene, silicones, proteins (collagen, elastin), alkanolamines, silicon oxides, metal oxides or sodium hexametaphosphate.

As is known, silicones are organosilicon polymers or oligomers comprising a linear or cyclic and branched or crosslinked structure, of variable molecular weight, obtained by polymerization and/or polycondensation of suitably functionalized silanes and essentially constituted of a repetition of main units in which the silicon atoms are connected to each other via oxygen atoms (siloxane bond), optionally substituted hydrocarbon-based radicals being connected directly to said silicon atoms via a carbon atom.

The term "silicones" also encompasses the silanes required for their preparation, in particular alkylsilanes.

The silicones used for coating the pigments that are suitable for the present invention are preferably chosen from the group containing alkylsilanes, polydialkylsiloxanes and polyalkylhydrogenosiloxanes. Even more preferentially, the silicones are chosen from the group containing octyltrimethylsilane, polydimethylsiloxanes and polymethylhydrogenosiloxanes.

Needless to say, before being treated with silicones, the metal oxide pigments may have been treated with other surface agents, in particular with cerium oxide, alumina, silica, aluminum compounds or silicon compounds, or mixtures thereof

The coated pigments are, for example, titanium oxides that have been coated:

- with silica, such as the product Sunveil from Ikeda and the product Eusolex T-AVO from the company Merck,

- with silica and iron oxide, such as the product Sunveil F from from the company Ikeda,

- with silica and alumina, such as the products Microtitanium Dioxide MT 500 SA and Microtitanium Dioxide MT 100 SA from the company Tayca, Tioveil from the company Tioxide and Mirasun TiW 60 from the company Rhodia,

- with alumina, such as the products Tipaque TTO-55 (B) and Tipaque TTO-55 (A) from the company Ishihara and UVT 14/4 from the company Kemira,

- with alumina and aluminum stearate, such as the product Microtitanium Dioxide MT 100 TV, MT 100 TX, MT 100 Z and MT-01 from the company Tayca, and the products Solaveil CT-10 W, Solaveil CT 100 and Solaveil CT 200 from the company Uniqema,

- with silica, alumina and alginic acid, such as the product MT-100 AQ from the company Tayca,

- with alumina and aluminum laurate, such as the product Microtitanium Dioxide MT 100 S from the company Tayca, - with iron oxide and iron stearate, such as the product Microtitanium Dioxide MT 100 F from the company Tayca,

- with zinc oxide and with zinc stearate, such as the product BR351 from the company Tayca,

- with silica and alumina and treated with a silicone, such as the products Microtitanium Dioxide MT 600 SAS, Microtitanium Dioxide MT 500 SAS or Micro titanium Dioxide MT 100 SAS from the company Tayca,

- with silica, alumina and aluminum stearate and treated with a silicone, such as the product STT-30-DS from the company Titan Kogyo,

- with silica and treated with a silicone, such as the product UV-Titan X 195 from the company Kemira or the product SMT-100 WRS from the company Tayca,

- with alumina and treated with a silicone, such as the products Tipaque TTO-55 (S) from the company Ishihara or UV Titan M 262 from the company Kemira,

- with triethanolamine, such as the product STT-65-S from the company Titan Kogyo,

- with stearic acid, such as the product Tipaque TTO-55 (C) from the company Ishihara,

- with sodium hexametaphosphate, such as the product Microtitanium Dioxide MT 150 W from the company Tayca.

Other titanium oxide pigments treated with a silicone are, for example, Ti0₂ treated with octyltrimethylsilane, such as the product sold under the trade name T 805 by the company Degussa Silices, Ti0₂ treated with a polydimethylsiloxane, such as the product sold under the trade name 70250 Cardre UF Ti0₂SF by the company Cardre, anatase/rutile Ti0₂ treated with a polydimethylhydrogenosiloxane, such as the product sold under the trade name Microtitanium Dioxide USP Grade Hydrophobic by the company Color Techniques.

The uncoated titanium oxide pigments are sold, for example, by the company Tayca under the trade names Microtitanium Dioxide MT 500 B or Micro titanium Dioxide MT 600 B, by the company Degussa under the name P 25, by the company Wackher under the name Transparent titanium oxide PW, by the company Miyoshi Kasei under the name UFTR, by the company Tomen under the name ITS and by the company Tioxide under the name Tioveil AQ.

The uncoated zinc oxide pigments are, for example:

- those sold under the name Z-Cote by the company Sunsmart, - those sold under the name Nanox by the company Elementis,

- those sold under the name Nanogard WCD 2025 by the company Nanophase Technologies.

The coated zinc oxide pigments are, for example:

- those sold under the name Z-Cote HP1 by the company Sunsmart (dimethicone-coated ZnO),

- those sold under the name Zinc Oxide CS-5 by the company Toshibi (polymethylhydrogenosiloxane-coated ZnO),

- those sold under the name Nanogard Zinc Oxide FN by the company Nanophase Technologies (as a 40% dispersion in Finsolv TN, Ci₂-Ci₅ alkyl benzoate),

- those sold under the names Daitopersion Zn-30 and Daitopersion Zn-50 by the company Daito (dispersions in oxyethylenated polydimethylsiloxane/cyclopolymethylsiloxane comprising 30% or 50% of zinc oxides coated with silica and polymethylhydrogenosiloxane),

- those sold under the name NFD Ultrafine ZnO by the company Daikin (ZnO coated with perfluoroalkyl phosphate and copolymer based on perfluoroalkylethyl as a dispersion in cyclopentasiloxane),

- those sold under the name SPD-Z1 by the company Shin-Etsu (ZnO coated with silicone-grafted acrylic polymer, dispersed in cyclodimethylsiloxane),

- those sold under the name Escalol Z100 by the company ISP (alumina-treated ZnO dispersed in an ethylhexyl methoxycinnamate/PVP-hexadecene copolymer/methicone mixture),

- those sold under the name Fuji ZnO-SMS-lO by the company Fuji Pigment (ZnO coated with silica and polymethylsilsesquioxane),

- those sold under the name Nanox Gel TN by the company Elementis (ZnO dispersed at a concentration of 55% in Ci₂-Ci₅ alkyl benzoate with hydroxystearic acid poly condensate).

The uncoated cerium oxide pigments are sold, for example, under the name Colloidal Cerium Oxide.

The uncoated iron oxide pigments are sold, for example, by the company Arnaud under the names Nanogard WCD 2002 (FE 45B), Nanogard Iron FE 45 BE AQ, Nanogard FE 45R AQ and Nanogard WCD 2006 (FE 45R) or by the company Mitsubishi under the name TY-220.

The coated iron oxide pigments are sold, for example, by the company Arnaud under the names Nanogard WCD 2008 (FE 45B FN), Nanogard WCD 2009 (FE 45B 556), Nanogard FE 45 BE 345 and Nanogard FE 45 BL or by the company BASF under the name Transparent Iron Oxide.

Mention may also be made of mixtures of metal oxides, in particular of titanium dioxide and of cerium dioxide, including the equal- weight mixture of titanium dioxide and cerium dioxide coated with silica, sold by the company Ikeda under the name Sunveil A, and also the mixture of titanium dioxide and zinc dioxide coated with alumina, silica and silicone, such as the product M 261 sold by the company Kemira, or coated with alumina, silica and glycerol, such as the product M 211 sold by the company Kemira.

The pigments may be introduced into the compositions according to the invention in their native form or in the form of a pigmentary paste, i.e. as a mixture with a dispersant, as described, for example, in document GB 2 206 339.

According to one embodiment, the amount of the mineral UV-screening agent(s) present in the composition according to the invention may range from 0.01% to 20% by mass, relative to the total mass of the composition. It ranges, for example, from 1% to 15% by mass, relative to the total mass of the composition.

According to a particular embodiment, the composition according to the invention also comprises one or more organic UV-screening agents and one or more mineral UV-screening agents.

According to a particular embodiment, the composition according to the invention also comprises a combination of UV-screening agents as described in patent FR 2 977 490, patent application WO 2013/004777 or patent application US 2014/0134120.

According to a particular embodiment, the composition according to the invention also comprises a UV-screening agent chosen from butylmethoxydibenzoylmethane, homosalate, octocrylene and ethylhexyl salicylate.

Antiaging active agent

According to a particular embodiment of the invention, the composition may comprise at least one antiaging active agent. Such an antiaging active agent may be chosen especially from moisturizers, desquamating agents, agents for improving the barrier function, depigmenting agents, antioxidants, dermo-decontracting agents, anti-glycation agents, agents for stimulating the synthesis of dermal and/or epidermal macromolecules and/or for preventing their degradation, agents for stimulating fibroblast or keratinocyte proliferation and/or keratinocyte differentiation, agents for promoting the maturation of the homy envelope, NO-synthase inhibitors, peripheral benzodiazepine receptor (PBR) antagonists, agents for stimulating the energy metabolism of cells, tensioning agents, and agents for promoting the cutaneous microcirculation.

In particular, the antiaging active agent may be present in a composition according to the invention in a content of between 0.001% and 10% by weight and preferably between 0.01% and 5% by weight relative to the total weight of the composition.

Filler

According to one embodiment, the composition according to the invention may also comprise at least one filler.

According to one variant, the filler is an inorganic (mineral) filler.

According to one variant, the filler is an organic filler.

According to one variant, the fillers present in the composition are a mixture of at least one inorganic (mineral) filler and of at least one organic filler.

The filler may be chosen from pigments, titanium oxide, red iron oxide, yellow iron oxide, black iron oxide, boron nitride, nacres, synthetic or natural mica, nacres comprising mica and titanium oxide, silica powder, talc, polyamide particles and in particular those sold under the name Orgasol by the company Atochem, polyethylene powders, microspheres based on acrylic copolymers, such as those made of ethylene glycol dimethacrylate/lauryl methacrylate copolymer sold by the company Dow Coming under the name Polytrap, expanded powders such as hollow microspheres and in particular the microspheres sold under the name Expancel by the company Kemanord Plast or under the name Micropearl F 80 ED by the company Matsumoto, silicone resin microbeads such as those sold under the name Tospearl by the company Toshiba Silicone, and mixtures thereof. These fillers may be present in amounts ranging from 0 to 20% by mass and preferably from 1% to 10% by mass relative to the total mass of the composition.

Preferably, the mass concentrations of filler range from 0.1% to 30%, and preferably from 0.5% to 15%, by mass relative to the total mass of said composition.

Emulsifier

According to one embodiment, the composition according to the invention may also comprise at least one emulsifier.

When the composition according to the invention is a water-in-oil (W/O) or oil-in-water (O/W) emulsion, the proportion of the oily phase of the emulsion may range from 5% to 80% by mass, and preferably from 5% to 50% by mass, relative to the total mass of the composition. The emulsions generally contain at least one emulsifier chosen from amphoteric, anionic, cationic and nonionic emulsifiers, used alone or as a mixture, and optionally a coemulsifier. The emulsifiers are chosen in an appropriate manner according to the emulsion to be obtained (W/O or O/W emulsion). The emulsifier and the coemulsifier are generally present in the composition in a proportion possibly ranging, for example, from 0.3% to 30% by mass and preferably from 0.5% to 20% by mass relative to the total mass of the composition.

For the W/O emulsions, examples of emulsifiers that may be mentioned include silicone emulsifiers such as dimethicone copolyols and (C8-Cl6)alkyldimethicone copolyols. One or more coemulsifiers may also be added thereto. The coemulsifier may be advantageously chosen from the group comprising polyol alkyl esters. Polyol alkyl esters that may especially be mentioned include glycerol and/or sorbitan esters, for example polyglyceryl isostearate, such as the product sold under the name Isolan GI 34 by the company Goldschmidt, sorbitan isostearate, such as the product sold under the name Arlacel 987 by the company ICI, sorbitan glyceryl isostearate, such as the product sold under the name Arlacel 986 by the company ICI, and any mixture thereof.

For the O/W emulsions, examples of emulsifiers that may be mentioned include nonionic surfactants, and especially esters of polyols and of fatty acids with a saturated or unsaturated chain including, for example, from 8 to 24 carbon atoms and better still from 12 to 22 carbon atoms, and the oxyalkylenated derivatives thereof, i.e. derivatives including oxyethylenated and/or oxypropylenated units, such as the glyceryl esters of C₈-C₂₄ fatty acids, and the oxyalkylenated derivatives thereof; the polyethylene glycol esters of Cs-C₂₄ fatty acids, and the oxyalkylenated derivatives thereof; the sorbitol esters of C^’s-C₂₄ fatty acids, and the oxyalkylenated derivatives thereof; the sugar (sucrose, glucose or alkylglucose) esters of C^’s-C₂₄ fatty acids, and the oxyalkylenated derivatives thereof; fatty alcohol ethers; the sugar ethers of C^’s-C₂₄ fatty alcohols, and mixtures thereof

According to a particular embodiment, the concentration of emulsifiers in the composition according to the invention ranges from 0.001% to 20% and preferably from 0.5% to 10% by mass, relative to the total mass of the composition.

Preserving agent

According to one embodiment, the composition according to the invention may also comprise at least one preserving agent.

Advantageously, the preserving agent is a preserving agent usually used in cosmetics. It may be chosen from the positive list contained in Annex VI of Regulation (EC) No 1223/2009, which specifies the list of preserving agents permitted in cosmetics.

According to one variant, the preserving agent(s) are present in the composition in a mass concentration of from 0.001% to 10% and preferably from 0.1% to 2%, relative to the total mass of the composition.

Polyol

According to a preferred embodiment, the aqueous phase of a composition according to the invention also comprises at least one alcohol, chosen especially from polyols, in particular chosen from glycols.

Thus, the composition may also comprise a polyol chosen from propylene glycol, 1, 3-propanediol, dipropylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, glycerol and sugars such as sorbitol, (poly)alkylene glycols, and any mixture thereof.

According to one embodiment, the mass concentrations of polyol range from 0.01% to 40% by mass relative to the total mass of said composition.

Preferably, the mass concentrations of polyol range from 0.1% to 30% and preferably from 5% to 25% by mass relative to the total mass of said composition. Thickener

Depending on the fluidity of the composition that it is desired to obtain, one or more thickeners and/or gelling agents, which are in particular hydrophilic, that is to say water-soluble or water-dispersible, may be incorporated into the composition. Examples of hydrophilic gelling agents that may be mentioned include modified or unmodified carboxyvinyl polymers, such as the products sold under the names Carbopol (CTFA name: carbomer) and Pemulen (CTFA name: Acrylates/C 10-30 alkyl acrylate crosspolymer) by the company Goodrich; polyacrylamides; optionally crosslinked and/or neutralized 2- acrylamido-2-methylpropanesulfonic acid polymers and copolymers, for instance the poly(2-acrylamido-2-methylpropanesulfonic acid) sold by the company Hoechst under the name Hostacerin AMPS (CTFA name: Ammonium polyacryldimethyltauramide); crosslinked anionic copolymers of acrylamide and of AMPS, which are in the form of a W/O emulsion, such as those sold under the name Sepigel 305 (CTFA name: Polyacrylamide/C 13- 14 isoparaffin/Faureth-7) and under the name Simulgel 600 (CTFA name: Acrylamide/Sodium acryloyldimethyltaurate copolymer/Isohexadecane/Polysorbate 80) by the company SEPPIC; polysaccharide biopolymers, for instance xanthan gum, guar gum, alginates and modified celluloses; and mixtures thereof. The amount of gelling agents depends on the desired objective.

According to one embodiment, the amount of gelling agents ranges for example from 0.01% to 10%, for example from 0.1% to 5% by mass, relative to the total mass of the composition.

Oily phase

When the composition used according to the invention comprises an oily phase, it preferably contains at least one oil, in particular one cosmetic oil. It may also contain other fatty substances.

As oils that may be used in the composition of the invention, mention may be made, for example, of:

- hydrocarbon-based oils of animal origin, such as perhydrosqualene;

- hydrocarbon-based oils of plant origin, such as liquid fatty acid triglycerides containing from 4 to 10 carbon atoms, for instance heptanoic or octanoic acid triglycerides, or alternatively, for example, sunflower oil, com oil, soybean oil, marrow oil, grapeseed oil, sesame seed oil, hazelnut oil, apricot oil, macadamia oil, arara oil, castor oil, avocado oil, caprylic/capric acid triglycerides, for instance those sold by the company Stearinerie Dubois or those sold under the names Miglyol 810, 812 and 818 by the company Dynamit Nobel, jojoba oil and shea butter oil;

- synthetic esters and ethers, especially of fatty acids, for instance the oils of formulae R1COOR2 and R1OR2 in which Ri represents a fatty acid residue including from 8 to 29 carbon atoms and R2 represents a branched or unbranched hydrocarbon-based chain containing from 3 to 30 carbon atoms, for instance purcellin oil, isononyl isononanoate, isopropyl myristate, 2-ethylhexyl palmitate, 2-octyldodecyl stearate, 2-octyldodecyl erucate or isostearyl isostearate;

- hydroxylated esters, for instance isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate, and fatty alkyl heptanoates, octanoates and decanoates;

- polyol esters, for instance propylene glycol dioctanoate, neopentyl glycol diheptanoate and diethylene glycol diisononanoate;

- pentaerythritol esters, for instance pentaerythrityl tetraisostearate;

- linear or branched hydrocarbons of mineral or synthetic origin, such as volatile or non volatile liquid paraffins, and derivatives thereof, hydrocarbon-based oils bearing a branched chain including from 10 to 20 carbon atoms, such as isohexadecane, isododecane, isoparaffins and mixtures thereof, petroleum jelly, polydecenes, and hydrogenated polyisobutene such as Parleam oil^®;

- natural or synthetic essential oils, for instance eucalyptus oil, hybrid lavender oil, lavender oil, vetiver oil, litsea cubeba oil, lemon oil, sandalwood oil, rosemary oil, camomile oil, savory oil, nutmeg oil, cinnamon oil, hyssop oil, caraway oil, orange oil, geraniol oil, cade oil and bergamot oil;

- fatty alcohols and fatty acids containing from 8 to 26 carbon atoms, for instance cetyl alcohol or acid, stearyl alcohol, stearic acid, a mixture of cetyl alcohol and of stearyl alcohol (cetylstearyl alcohol), octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2- undecylpentadecanol, oleyl alcohol or linoleyl alcohol;

- partially hydrocarbon-based and/or silicone-based fluoro oils, such as those described in document JP 2295912;

- silicone oils, for instance volatile or non-volatile polymethylsiloxanes (PDMS) with a linear or cyclic silicone chain, which are liquid or pasty at room temperature, especially cyclopolydimethylsiloxanes (cyclomethicones) such as cyclohexasiloxane; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups, which are pendent or at the end of a silicone chain, these groups containing from 2 to 24 carbon atoms; phenylsilicones, for instance phenyl trimethicones, phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyl dimethicones, diphenylmethyldiphenyltrisiloxanes or 2-phenylethyl trimethylsiloxy silicates, and polymethylphenylsiloxanes; and

- mixtures thereof

In the list of oils mentioned above, the term“hydrocarbon-based oil” means any oil mainly including carbon and hydrogen atoms, and possibly ester, ether, fluoro, carboxylic acid and/or alcohol groups.

The other fatty substances that may be present in the oily phase are, for example, fatty acids containing from 8 to 30 carbon atoms, for instance stearic acid, lauric acid, palmitic acid and oleic acid; waxes, for instance lanolin wax, beeswax, camauba wax or candelilla wax, paraffin wax, lignite wax or microcrystalline waxes, ceresin or ozokerite, and synthetic waxes, for instance polyethylene waxes and Fischer-Tropsch waxes; silicone resins such as trifluoromethyl-Ci-C₄-alkyl dimethicone and trifluoropropyl dimethicone; and silicone elastomers, for instance the products sold under the name KSG by the company Shin-Etsu, under the names“Trefil”,“BY29” or““ by the company Dow Coming, or under the name Gransil by the company Grant Industries.

These fatty substances may be chosen in a varied manner by a person skilled in the art in order to prepare a composition having the desired properties, for example in terms of consistency or texture.

Preferably, a composition according to the invention also comprises a fatty phase containing at least one fatty substance.

According to one variant, the amount of oily phase may range, for example, from 0.01% to 60%, for example from 5% to 50% by mass, relative to the total mass of the composition.

According to one variant, the amount of oily phase may range, for example, from 10% to 40% by mass relative to the total mass of the composition. According to one embodiment, the composition also comprises a fragrance.

According to one variant, the amount of fragrances may range, for example, from 0.001% to 10% and preferably from 0.01% to 5% by mass relative to the total mass of the composition.

According to a particular embodiment, the composition comprises at least one hydrotropic molecule, for instance nicotinamide (vitamin B3), caffeine, sodium PCA, sodium salicylate, urea, hydroxyethyl urea, and any mixture thereof.

The compositions, especially the cosmetic compositions, according to the invention comprise a physiologically acceptable medium.

Within the meaning of the present invention, the term “physiologically acceptable medium” is intended to denote a medium that is suitable for the topical administration of a composition.

A physiologically acceptable medium generally has no unpleasant odor or appearance, and is entirely compatible with topical administration. In the present case, where the composition is intended for topical administration, i.e. by application at the surface of the keratin material under consideration, such a medium is considered in particular to be physiologically acceptable when it does not cause stinging, tautness or redness that is unacceptable to the user.

In particular, the composition is suited to topical application, that is to say application on the surface of the skin, the scalp and/or the mucous membrane under consideration. Thus, the physiologically acceptable medium is preferentially a cosmetically or dermatologically acceptable medium, i.e. a medium that has no unpleasant odor, color or appearance, and that does not cause the user any unacceptable stinging, tautness or redness.

The composition may then comprise any constituent usually used in the envisaged application.

Needless to say, a person skilled in the art will take care to select this or these optional additional compound(s), and/or the amount thereof, such that the advantageous properties of the compounds according to the invention are not, or are not substantially, adversely affected by the envisaged addition.

The composition according to the invention may be more or less fluid and may have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste or a foam. It may optionally be applied to the skin in aerosol form. It may also be in solid form, for example in the form of a stick.

The compositions according to the invention may be in the form of products for caring for the skin or semi-mucous membranes, such as a protective or cosmetic care composition for the face, for the lips, for the hands, for the feet, for the anatomical folds or for the body (for example, day creams, night cream, day serum, night serum, makeup- removing cream, makeup base, antisun composition, protective or care body milk, aftersun milk, skincare or scalp-care lotion, gel or foam, serum, mask, or aftershave composition).

The cosmetic compositions according to the invention may be used, for example, as care products and/or antisun protection products for the face and/or the body, of liquid to semiliquid consistency, such as lotions, milks, more or less rich creams, gels and cream-gels. They may optionally be packaged in aerosol form and may be in the form of a mousse or a spray.

The compositions according to the invention in the form of vaporizable fluid lotions in accordance with the invention are applied to the skin or hair in the form of fine particles by means of pressurized or non-pressurized vaporizing devices. The devices in accordance with the invention are well known to those skilled in the art and comprise non aerosol pumps or "atomizers", aerosol containers comprising a propellant and aerosol pumps using compressed air as propellant. The latter are described in patents US 4 077 441 and US 4 850 517 (forming an integral part of the content of the description).

The compositions packaged in aerosol form in accordance with the invention generally contain conventional propellants, for instance hydro fluoro compounds, dichlorodifluoromethane, difluoroethane, dimethyl ether, isobutane, n-butane, propane or trichlorofluoromethane. They are preferably present in amounts ranging from 15% to 80% by weight relative to the total weight of the composition.

Such compositions as defined previously may especially be employed for a cosmetic use according to the invention.

Preferably, a composition according to the invention is a composition for caring for keratin materials, preferably for caring for the skin.

A composition according to the invention preferably has a viscosity of between 0.1 Pa.s and 50 Pa.s, better still between 0.2 Pa.s and 40 Pa.s, and even better still between 0.5 Pa.s and 25 Pa.s.

The viscosity of the composition is measured at room temperature (20°C) at a shear rate of 200 s ¹ by using a Rheomat RM 180 (Brookfield) viscometer equipped with a No. 3 spindle, the measurement being performed after 10 minutes of rotation of the spindle (after which time stabilization of the viscosity and of the spin speed of the spindle are observed).

Throughout the description, including the claims, the term "comprising a" should be understood as being synonymous with "comprising at least one", unless otherwise specified.

The expressions "between ... and and "ranging from ... to ..." should be understood as meaning limits included, unless otherwise specified.

In the description and the examples, the percentages are percentages by weight, unless otherwise indicated. The percentages are thus given by weight relative to the total weight of the composition. The temperature is expressed in degrees Celsius, unless otherwise indicated, and the pressure is atmospheric pressure, unless otherwise indicated.

The invention is illustrated in greater detail by the nonlimiting examples presented below.

EXAMPLES

Fourteen care compositions were prepared.

Compositions 1, 2, 3, 5, and 9-11 are comparative compositions comprising baicalin but not any antioxidants in accordance with the present invention.

Compositions 4, 6-8 and 12, according to the invention comprise baicalin and antioxidants in accordance with the present invention.

1/ Preparation of the compositions

The compositions were prepared from the weight proportions detailed in the tables below and according to the following preparation protocol:

Preparation o f phase A

The starting materials are first weighed out carefully using a balance (precision = 0.01 g), they are heated to a temperature of 75°C using a hotplate, and are mixed with a magnetic bar.

Preparation of phase B

Phase B is heated at 80°C and mixed using a magnetic bar.

The emulsion is prepared by dispersing phase B into phase A using a Moritz rotor-stator. The stirring is maintained for 10 minutes.

Addition of phase C

Phase C was introduced into phase A+B at 60°C. Stirring is continued for 15 minutes until a homogeneous preparation is obtained. The preparation is cooled to 50°C.

Addition of phase D

Phase D is introduced into phase A+B+C with stirring using a Rayneri blender. Addition of phase E

Phase E is introduced into phase A+B+C+D with stirring using a Rayneri blender at a temperature below 35°C.

Addition of phase F

The pH is adjusted at the end of formulation using 5% citric acid to a pH =

5.5±0.3

2/ Evaluation of the cosmetic properties

The colorimetric properties of the compositions were evaluated according to the following protocol.

The color of the compositions was evaluated after preparing 50 pm thin films on a contrast card, using a film spreader.

The colorimetric measurements were then taken using a Minolta CM2600D spectrocolorimeter at two points on the film.

The results are expressed in the (L*, a*, b*) system, in which L* represents the luminance, a* represents the red-green axis (-a* = green, +a* = red) and b* represents the yellow-blue axis (-b* = blue, +b* = yellow). Thus, a* and b* express the hue of the compound. For each formulation, the color was measured at t = 0, and then again at t = 2 months (after storage at 45°C).

The color difference DE* was thus measured for each composition according to the following formula:

(DE*)² = (AL*)² + (Aa*)² + (Ab*)²

AL* = L* formulations at t = 0 - L* formulations at t = 2 months

Aa* = a* formulations at t = 0 - a* formulations at t = 2 months

Ab* = b* formulations at t = 0 - b* formulations at t = 2 months

The higher the value of DE*, the greater the color change after 2 months.

This color change may be attributed to the instability of baicalin in the composition. Thus, the higher the value of DE*, the more unstable baicalin is in the composition.

When the value of DE* is less than or equal to 6.00, it is considered that the color variation is acceptable. Above this value, the composition comprising baicalin exhibits browning which degrades the visual aspect of the product.

3/ Care compositions 1 to 4

The following compositions (comparative and according to the invention) comprise 0.5% by weight of baicalin.

⁽¹⁾ sold by the company Croda under the name Arlacel 165

⁽²⁾ sold by the company Dow Coming under the name Dowsil S 200 fluid 100 cst

⁽³⁾ sold by the company Clariant under the name Hostacerin AMPS

⁽⁴⁾ sold by the company Dow Coming under the name Xiameter PMX-1503 Fluid

(⁵⁾ sold by the company Takemoto under the name NLK506

⁽⁶⁾ sold by the company Shin-Etsu under the name KSG16

⁽⁷⁾ sold by the company Merck under the name Oxynex ST

⁽⁸⁾ sold by the company MMP under the name Baicalin 95MM

The colorimetric properties of compositions 1 to 4 were evaluated according to the protocol presented previously. The results are given in the table below:

It emerges from these results that the compositions in accordance with the invention do not undergo any prohibitive color variation after 2 months of storage at 45°C. Baicalin is thus stable in these compositions.

In contrast, the compositions outside the invention show a substantial color variation after 2 months of storage, which is reflected by visible yellowing of the composition associated with a lack of stability of baicalin.

4/ Care compositions 5 to 8

The following compositions (comparative and according to the invention) comprise 1% by weight of baicalin.

⁽¹⁾ sold by the company Croda under the name Arlacel 165

⁽³⁾ sold by the company Clariant under the name Hostacerin AMPS

⁽⁴⁾ sold by the company Dow Coming under the name Xiameter PMX-1503 Fluid ⁽⁵⁾ sold by the company Takemoto under the name NLK506

⁽⁶⁾ sold by the company Shin-Etsu under the name KSG16 (V) sold by the company Merck under the name Oxynex ST

(8) sold by the company MMP under the name Baicalin 95MM

The colorimetric properties of compositions 5 to 8 were evaluated according to the protocol presented previously.

The results are given in the table below:

As for the preceding compositions, the compositions in accordance with the invention do not undergo any prohibitive color variation after 2 months of storage at 45°C. Baicalin is thus stable in these compositions.

In contrast, the compositions outside the invention show a substantial color variation after 2 months of storage, which is reflected by visible browning of the composition associated with a lack of stability of baicalin.

5/ Care compositions 9 to 12

The following comparative compositions comprise 2.5% by weight of baicalin.

⁽¹⁾ sold by the company Croda under the name Arlacel 165

⁽³⁾ sold by the company Clariant under the name Hostacerin AMPS

⁽⁴⁾ sold by the company Dow Coming under the name Xiameter PMX-1503 Fluid (⁵⁾ sold by the company Takemoto under the name NLK506

⁽⁶⁾ sold by the company Shin-Etsu under the name KSG16 ⁽⁷⁾ sold by the company BASF under the name Tinogard TT

⁽⁸⁾ sold by the company Merck under the name Oxynex ST

⁽⁹⁾ sold by the company MMP under the name Baicalin 95MM The colorimetric properties of compositions 9 to 12 were also evaluated according to the protocol presented previously.

The results are given in the table below:

It emerges from these results that the compositions outside the invention show a substantial color variation after 2 months of storage, which is reflected by visible browning of the composition associated with a lack of stability of baicalin.

In contrast, the composition in accordance with the invention does not undergo any prohibitive color variation after 2 months of storage at 45°C.

Claims

1. A composition, preferably a cosmetic composition, comprising at least one aqueous phase containing:

2. The composition as claimed in claim 1, characterized in that baicalin or a derivative thereof is chosen from the compounds of the general formula (I) below:

in which:

- each R_y independently denotes R, or a -(C2-Cio)alkenyl, -(C2-Cio)alkynyl, -(C₃- Cio)cycloalkyl, -(C8-Ci₄)bicycloalkyl, -(C8-Ci₄)tricycloalkyl, -(C5-Cio)cycloalkenyl, -(CV Ci₄)tricycloalkenyl, phenyl, naphthyl or -(Ci₄)aryl radical, each possibly being substituted with one or more radicals R_z;

- each Ri, R₂ and R₃ independently denotes R_q or a -(C2-Cio)alkenyl, -(C2-Cio)alkynyl, - (C₃-C io)cycloalkyl, -(C8-Ci₄)bicycloalkyl, -(C8-Ci₄)tricycloalkyl, -(C5-Cio)cycloalkenyl, - (C₈-C i₄)tricycloalkenyl, phenyl, naphthyl or -(Ci₄)aryl radical, each possibly being substituted with one or more radicals R_z;

- R_f is H, (Ci-Ci₂)alkyl, optionally substituted with 1 to 5 R_y or (Ci-Ci₂)alkyl-0-(Ci- Ci₂)alkyl radicals, each (Ci-Ci₂)alkyl radical possibly being substituted with 1 to 5 groups

R_y;

- n is 0, 1, 2, 3, 4 or 5;

3. The composition as claimed in either of the preceding claims, characterized in that it comprises baicalin corresponding to the general formula (II) below:

or a plant extract containing same.

4. The composition as claimed in any one of the preceding claims, characterized in that baicalin or a derivative thereof is present in a content of greater than or equal to 0.01% by weight of active material, preferably greater than or equal to 0.1% by weight, better still greater than or equal to 0.2% by weight, relative to the total weight of the composition, and preferably in a content of between 0.01% and 5% by weight of active material, preferably between 0.1% and 4% by weight, and more particularly between 0.2% and 3% by weight, relative to the total weight of the composition.

5. The composition as claimed in any one of the preceding claims, characterized in that the antioxidant compound is present in a content ranging from 0.2% to 10.0% by weight, preferably ranging from 0.3% to 5.0% by weight and better still ranging from 0.5% to 3.0% by weight relative to the total weight of the composition.

6. The composition as claimed in any one of the preceding claims, characterized in that the antioxidant compound is chosen from 4- hydroxybenzylidenemalonate derivatives, 4-hydroxycinnamate derivatives and/or mixtures thereof, and in particular from the compounds of formula (III) below, and also the tautomeric forms thereof, the optical isomers thereof, the geometrical isomers thereof and/or mixtures thereof:

in which:

- R₁₅ denotes a linear or branched Ci-C₈ alkyl radical.

7. The composition as claimed in any one of the preceding claims, characterized in that the antioxidant compound is chosen from the compounds of formula (Ilia) below, and also the tautomeric forms thereof, the optical isomers thereof, the geometric isomers thereof and/or mixtures thereof:

in which:

- Rie is chosen from -C(0)CH₃, -C0₂Ri₈, -C(0)NH₂ and -C(0)N(Ri₉)₂;

- X denotes O or NH;

- Rn represents a linear or branched C₁-C₃₀ alkyl radical;

- Ris represents a linear or branched Ci-C₂o alkyl radical;

8. The composition as claimed in any one of the preceding claims, characterized in that the antioxidant compound is chosen from the compounds of formula (Illb) or (IIIc) below, and also the tautomeric forms thereof, the optical isomers thereof, the geometrical isomers thereof and/or mixtures thereof:

in which:

- Ri₆ denotes -C0₂Ri8;

- Rn denotes a linear or branched Ci-C₈ alkyl;

- Ris denotes a linear or branched Ci-Cs alkyl;

- X denotes O.

9. The composition as claimed in any one of the preceding claims, characterized in that the antioxidant compound is chosen from diethylhexyl syringylidenemalonate of formula (Hid) below:

and also the tautomeric forms thereof, the optical isomers thereof, and/or mixtures thereof.

10. The composition as claimed in any one of the preceding claims, characterized in that the mass ratio of baicalin or derivative(s)/antioxidant compound is between 1 :50 and 30:1, preferably between 1 :20 and 20:1, in particular between 1 :10 and 15:1 and more preferentially between 3:10 and 10:1.

11. The composition as claimed in any one of the preceding claims, characterized in that the composition also comprises an antiaging active agent and/or an anti-UV active agent.

12. The composition as claimed in any one of the preceding claims, characterized in that the aqueous phase also comprises at least one alcohol, chosen especially from polyols, in particular chosen from glycols.

13. The composition as claimed in any one of the preceding claims, characterized in that it is an emulsion, especially a water-in-oil or oil-in-water emulsion, and preferably an oil-in-water emulsion.

14. The composition as claimed in any one of the preceding claims, characterized in that it is a composition for caring for keratin materials, preferably for caring for the skin.

15. A cosmetic process comprising at least one step that consists in applying to the skin, the lips and/or the hair a composition as defined according to any one of claims 1 to 14.